NEWS

Processed and Red Meat Consumption Linked to Slight Increase in Risk of Pancreatic Cancer
January 18, 2012

Mutations in Genomic Integrity Gene Increase Hereditary Pancreatic Cancer Risk
January 6, 2012

Pancreatic, Neuroendocrine GI, and Adrenal Cancers
October 28, 2011

Sunitinib Approved as First Anti-VEGF Treatment for Advanced Pancreatic Neuroendocrine Tumors
May 23, 2011

Common Cancer Link May Unleash Potential of Antibodies
Oncology NEWS International, November 29, 2010

JOB LISTINGS

Post a job

Order Your Copy!
(2010, 13th Edition)

Please allow 3 – 4 weeks to ship

CONNECT WITH US

	Become a fan on Facebook
	Add us on Google Plus
	Follow us on Twitter
	Sign up for our Newsletters
	Subscribe to our RSS Feed

Pancreatic Cancer

Radiation Therapy in Resectable Pancreatic Cancer

REVIEW ARTICLE
Manisha Palta, Christopher Willett, Brian Czito; ONCOLOGY Vol. 25 No. 8
Older trials evaluating outcomes of CRT, CT, and surgery alone in patients with resected pancreatic cancer are fraught with flaws. Despite this, adjuvant CT alone has evolved and remains the standard of care in the adjuvant treatment of resectable pancreatic cancer throughout much of Europe.
• Clearing Up the Fog
Targeting the Insulin Growth Factor Pathway

REVIEW ARTICLE
Talia Golan, Milind Javle; ONCOLOGY Vol. 25 No. 6
Recently, randomized phase II trials combining IGF-1R with epidermal grown factor receptor (EGFR) inhibition in colorectal cancer have been completed. Preclinical studies have indicated that several biomarkers may have potential predictive value.
• Targeting IGF-1R: at a Crossroad
• The IGF-1R Pathway as a Therapeutic Target

REVIEW ARTICLES

Surgical Management of Neuroendocrine Tumors of the Gastrointestinal Tract
Lyen C. Huang, MD, MPH¹, George A. Poultsides, MD¹, Jeffrey A. Norton, MD¹ , August 15, 2011

This article reviews the surgical management of gastrointestinal neuroendocrine tumors, including the preoperative control of hormonal symptoms, extent of resection required, postoperative outcomes, and differing management strategies.
• Surgical Management of NETs: Treatment of Localized and Metastatic Disease
• NETs: a Heterogeneous Set of Neoplasms

Role of Radiation Therapy in Patients With Resectable Pancreatic Cancer
Manisha Palta, MD¹, Christopher Willett, MD¹, Brian Czito, MD¹ , July 11, 2011

Older trials evaluating outcomes of CRT, CT, and surgery alone in patients with resected pancreatic cancer are fraught with flaws. Despite this, adjuvant CT alone has evolved and remains the standard of care in the adjuvant treatment of resectable pancreatic cancer throughout much of Europe.
• Clearing Up the Fog

Targeting the Insulin Growth Factor Pathway in Gastrointestinal Cancers
Talia Golan, MD¹, Milind Javle, MD² , May 17, 2011

Recently, randomized phase II trials combining IGF-1R with epidermal grown factor receptor (EGFR) inhibition in colorectal cancer have been completed. Preclinical studies have indicated that several biomarkers may have potential predictive value.
• Targeting IGF-1R: at a Crossroad
• The IGF-1R Pathway as a Therapeutic Target

Treatment of Early-Stage Pancreatic Cancer
Emily H. Castellanos, MD¹ Dana B. Cardin, MD¹ Jordan D. Berlin, MD¹ , February 17, 2011

Early trials of adjuvant therapy in pancreatic cancer had multiple limitations including small sample size, population heterogeneity, and inability to distinguish between components of combined modality treatment.
• Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer
• Neoadjuvant Therapy in Potentially Resectable Pancreatic Cancer?

Recurrent Pancreatic Adenocarcinoma After Pancreatic Resection
Arvind Dasari, MD¹, Martin McCarter, MD², Martine C. McManus, MD, BAO, BCh³, Paul Russ, MD, FACR⁴, Wells A. Messersmith, MD, FACP⁵ , January 7, 2011

In spite of modern treatment modalities, resectable pancreatic cancer continues to have a high rate of recurrence and mortality.
• The War on Pancreatic Cancer: Are We Gaining Ground?
• Pancreatic Adeno-carcinoma: New Approaches to a Challenging Malignancy

MEDLINE

p8 expression controls pancreatic cancer cell migration, invasion, adhesion, and tumorigenesis.

pubmed.gov - 12/1/11

p8 is a stress gene whose activity is necessary for tumor development and progression. The acquisition of invasive properties by transformed cells is a key event in tumor development. In order to establish whether p8 is involved or not in this phenomenon, we assessed the capacity of p8 at influencing cell adhesion, migration, invasion, and tumorigenesis of pancreatic cancer cells. p8 expression was knocked down by a small interfering RNA (siRNA) in pancreatic cancer-derived Panc-1 and MiaPaCa-2 cells and subsequent changes in cell adhesion, migration, invasion, and tumorigenesis were assessed. Influence of p8 silencing on gene expression was analyzed using cDNA microarrays. The influence of inhibiting CDC42, one of the genes most over-expressed in p8-silenced cells, on the changes observed in p8-silenced cells was also evaluated. Finally, the tumorigenic capacities of Panc-1 cells transfected with control siRNA or p8 siRNA were compared by assessing their ability to form colonies in

Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling.

pubmed.gov - 11/15/11

Glutamate has been implicated in tumorigenesis through activation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (AMPAR). However, the function of a glutamate-to-AMPAR signal in pancreatic ductal adenocarcinoma (PDAC) has remained elusive. We now show that glutamate-mediated AMPA receptor activation increases invasion and migration of pancreatic cancer cells via activation of the classical MAPK pathway. Glutamate levels were increased in pancreatic cancer accompanied by downregulation of GluR subunits 1, 2, and 4. In pancreatic cancer precursor lesions, pancreatic intraepithelial neoplasia (PanIN), GluR1 subunit levels were strikingly and step-wise increased but its expression was rare in PDAC. Pharmacological inhibition or RNAi-mediated suppression of GluR1 or GluR2 did not affect cancer cell growth but significantly decreased invasion. In a K-ras wildtype cell line, AMPA receptor activation enhanced K-ras activity and--further

Regional chemotherapy for pancreatic cancer.

pubmed.gov - 10/1/11

Pancreatic cancer complicated by splenic infarction and abscess.

pubmed.gov - 10/13/11

Pancreatic tail adenocarcinoma is both a diagnostic and therapeutic challenge. Despite technical and therapeutic advances, the prognosis remains dismal; the average survival time after diagnosis is characteristically only five to eight months. Both splenic infarction and abscess are very rare complications of pancreatic cancer. In this case of splenic infarction, the possible source of emboli should be carefully investigated. In addition, splenic abscess must be suspected in patients with splenic infarction, especially if the infectious signs persist despite appropriate treatment. Rapid diagnosis and treatment are essential as its course can prove fatal. The patient presented herein had a splenic infarct and abscess as complications of pancreatic tail carcinoma. The treatment of choice was splenectomy and distal pancreatectomy with resection of involved organs. The variability in clinical presentation and imaging studies warrants consideration of this entity in the differential

Alpha-fetoprotein-producing pancreatic cancer cells possess cancer stem cell characteristics.

pubmed.gov - 9/28/11

We aimed to demonstrate the existence of cancer stem cells in human pancreatic cancer, and to clarify that they are alpha-fetoprotein (AFP) producing cells. Six cell lines derived from human pancreatic cancers were examined, and AsPC-1 and PANC-1 were noted to express AFP. Single cell culture assays and xenotransplantation revealed that the AFP-producing cells had the capacity for self-renewal and differentiation, and that these cells were tumorigenic. Furthermore, they were resistant to anti-cancer agents. The ABCA12 transporter was expressed in the AFP-producing cells at a level more than twice as high as that in the non-AFP-producing cells. The AFP-producing cells were shown to be putative pancreatic cancer stem cells. Furthermore, the expression of ABCA12 appears to be associated with drug resistance.

CLINICAL TRIALS

Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract Cancer - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

Expression of Inflammatory Proteins in Pancreatic Cancer - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

TOPIC INDEX

Pancreatic Cancer

Radiation Therapy in Resectable Pancreatic Cancer

Targeting the Insulin Growth Factor Pathway